# OnCo record ck-301-101 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/ck-301-101/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "ck-301-101", "NCT03212404" ;
  schema:name "CK-301-101"@en ;
  schema:alternateName "Study CK-301-101"@en, "Cosibelimab pivotal study"@en ;
  schema:description "CK-301-101 was the first study of cosibelimab, and its skin squamous cell cancer groups, where about half of tumours shrank, led to the drug's US approval in December 2024."@en ;
  schema:url <https://onco.cc/trials/ck-301-101/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03212404>, <https://doi.org/10.1136/jitc-2023-007637>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06bdadd5-d2db-406f-a3f8-de47f48a52e3>, <https://doi.org/10.1016/j.jaad.2025.09.009> ;
  onco:status "active" ;
  onco:phase "1" ;
  onco:related <https://onco.cc/trials/empower-cscc-1/>, <https://onco.cc/trials/keynote-629/> ;
  onco:cancers <https://onco.cc/cancers/cutaneous-scc/>, <https://onco.cc/cancers/advanced-cutaneous-scc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/cosibelimab/> ;
  onco:companies <https://onco.cc/companies/checkpoint-therapeutics/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-ck-301-101-jitc-2023/> .